Compare Stocks

Actuant Corporation designs, manufactures, and distributes a range of industrial products and systems worldwide. It operates in two segments, Industrial Tools & Services (IT&S) and Engineered Components & Systems (EC&S). The IT&S segment designs, manufactures, and distributes branded hydraulic and mechanical tools; and provides services and tool rentals to the industrial, maintenance, infrastructure, oil and gas, energy, and other markets. This segment offers branded tools and engineered heavy lifting technology solutions, as well as connectors for oil and gas, and hydraulic torque wrenches; and energy maintenance and manpower services. It also provides high-force hydraulic and mechanical tools, including cylinders, pumps, valves, and specialty tools; and bolt tensioners, and connectors for oil and gas, as well as other products. This segment markets its branded tools and services primarily under the Enerpac, Hydratight, Larzep, Simplex, Biach, Equalizer, and Mirage brands through a localized product, rental, and maintenance depots. The EC&S segment designs, manufactures, and assembles system critical position and motion control systems, high performance ropes, cables and umbilicals, and other customized industrial components to various vehicle, construction, agricultural, and other niche markets. This segment offers actuation systems, mechanical power transmission products, engine air flow management systems, human to machine interface solutions, and other rugged electronic instrumentations; automotive convertible top actuation, hydraulic cab-tilt and latching, and automotive electro-hydraulic convertible top latching and actuation systems; and agriculture, off-highway, concrete tensioning, rope and cable and other product lines. It primarily markets its products directly to original equipment manufacturers, as well as to other customers through a technical sales organization. The company was founded in 1910 and is headquartered in Menomonee Falls, Wisconsin.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.